A global leader in the diagnostics of serum protein with a superior technology in electrophoresis.

Sebia is a research-driven company covering several pathologies including multiple myeloma, diabetes (HbA1c) and haemoglobin deficiencies.  Montagu originally acquired the business in 2006 and invested for a second time in 2014.

00

Revenue growth 2014-2018

00

Instruments in installed base

000

Countries products sold into

A Montagu business

  • A global leader in electrophoresis with cutting-edge technology
  • Highly recurring revenues
  • Strong market dynamics increasing demand and potential to grow emerging market sales

Supporting international expansion

Between 2014 and 2018, we supported Sebia:

  • In the successful launch and development of its new generation instrument the Capillarys 3
  • Accelerate penetration of the diabetes market
  • Complete the strategic acquisition of Italian competitor Interlab

Sebia was sold to a consortium of long term investors: Caisse de dépôt et placement du Québec (CDPQ), Téthys and CVC's long term fund.

Deal details


Year of entry

2014


Year of exit

2018


Country

France


Status

Realised


Industry Sector

Healthcare

Back to all portfolio